Search Results

You are looking at 1 - 8 of 8 items for :

  • "herpes simplex virus" x
Clear All
Full access

Michael Angarone and Michael G. Ison

Hemopoietic Stem Cell or Solid Organ Transplantation. 2nd ed. Philadelphia ; Lippincott Williams & Wilkins ; 2003 . 59. Schubert MM Peterson DE Flournoy N . Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow

Full access

Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann and Courtney Smith

Herpes Simplex Virus: Herpes simplex virus (HSV) is an important pathogen in patients who develop neutropenia and mucositis. HSV infections primarily result from reactivation of latent virus. The presence of latent HSV can be determined by pretreatment

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma and Dorothy A. Shead

experienced serious infectious complications requiring hospitalization. 20 Pathogens responsible for the infections were bacterial, viral (eg, herpes simplex virus [HSV], varicella zoster virus [VZV]), fungal, and opportunistic pathogens, including

Full access

Rupali Roy and Leo I. Gordon

cytomegalovirus and varicella zoster virus, whereas echovirus, influenza A, parvovirus B19, West Nile virus, BK virus, hepatitis C, herpes simplex virus, and even JC virus in association with rituximab have been seen. 48 The observation that progressive

Full access

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory and Hema Sundar

. 81 , 82 In particular, tuberculosis, progressive multifocal leukoencephalopathy, reactivation of hepatitis B virus, and herpes simplex virus have been reported in patients treated with ruxolitinib. 83 – 87 Patients should be monitored for signs and

Full access

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer and Hema Sundar

previously untreated CLL, it should not be used in the first line. Prescribers should be aware of this increased risk for infections in patients with relapsed or refractory CLL. Infection prophylaxis for herpes simplex virus, Pneumocystis jirovecii

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian and Anita Engh

-CSF) has shown modest response rates or stable disease in several small clinical studies. 98 – 101 These studies and others led to the development of T-VEC, an agent that uses a modified herpes simplex virus to induce tumor cell lysis and to deliver

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma and Kristina M. Gregory

with a fluoroquinolone (levofloxacin is preferred) should be considered in those with expected duration of neutropenia (ANC < 1000/mcL) of more than 7 days. Antiviral prophylaxis (acyclovir, valacyclovir, or famciclovir) is recommended in herpes simplex